Evaluation of Panel Reactive Antibody in Children Following Stage I Palliation for Hypoplastic Left Heart Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

33 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-03-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether children and adolescents 8-18 years of age with HLHS and related lesions who have undergone stage I palliation during infancy using an allograft patch demonstrate continued evidence of HLA antibody formation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients

NCT00284531

Cardiac Transplantation

TERMINATED PHASE1/PHASE2

Longitudinal Study for Relapsing Polychondritis

NCT04919538

Relapsing Polychondritis Vasculitis

RECRUITING

Daclizumab Experience in Pediatric Heart Transplant

NCT00486057

Congenital Disorders

TERMINATED

Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood

NCT01268033

Childhood Idiopathic Nephrotic Syndrome

COMPLETED PHASE2/PHASE3

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients

NCT03078582

Paroxysmal Nocturnal Hemoglobinuria (PNH)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be of a prospective cross-sectional design, consisting of three groups. The first two groups (study groups) will consist of (1) subjects with HLHS and other related lesions who have undergone stage I palliation using an allograft patch during infancy and (2) subjects with "single ventricle" lesions who have undergone stage II palliation using allograft without antecedent stage I palliation. The third group (control group) will consist of subjects who have undergone corrective or palliative surgery for CHD during infancy in which an allograft patch was not used, and in which there have been no further exposures to allograft. We have chosen to study both (1) subjects who have undergone stage I and II palliation and (2)subjects who have undergone stage II palliation only in an attempt to distinguish between sensitization that may occur from allograft exposure during stage I palliation and that which may occur during stage II palliation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group I

Study group I will include children who have undergone stage I palliation employing allograft material for left ventricular outflow tract reconstruction at CHOP during infancy (\<1 year of age). Stage I palliation is defined as an operation in which augmentation of the native ascending aorta and aortic arch is performed to bypass atresia or critical obstruction of the left heart structures.

No interventions assigned to this group

Study Group II

Study group II who have undergone stage II palliation in which allograft material is used, but have not undergone antecedent stage I palliation. Stage II palliation is defined as a superior cavopulmonary anastomosis in which the superior vena cava is anastomosed to the ipsilateral pulmonary artery via either the bidirectional Glenn or hemi-Fontan procedures.

No interventions assigned to this group

Control Group

The control group who have undergone palliative or corrective surgery for congenital heart disease during infancy (\<1 year of age) not requiring allograft material.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children and adolescents between 8 and 18 years of age.
* Parents/guardian permission (informed consent)
* Assent of the study subject
* Subjects followed within the CHOP Cardiology Division
* Operative note(s) available for review in medical record
* Have undergone stage I, stage II palliation, or corrective surgery for congenital heart disease during infancy (\<1 year of age) not requiring allograft material.

Exclusion Criteria

* Refusal or withdrawal of informed consent and/or assent.
* unavailability of medical records to confirm operative details.
* Additional surgeries (e.g., other than stage I or II palliation) utilizing allograft
* Exposure to allograft at any point in control group AGE \<8 or \>18 years
* Presence of genetic syndrome known to affect immunologic function (e.g., DiGeorge syndrome)

Minimum Eligible Age

8 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No